Benefits of Novel Oral Anticoagulant Agents for Thromboprophylaxis after Total Hip or Knee Arthroplasty
Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are among the most common orthopedic procedures performed in the United States, with almost 300,000 THA surgeries and more than 500,000 TKA surgeries performed annually.1 This number is projected to rise to approximately 572,000 annual THA surgeries and 3.5 million annual TKA surgeries by 2030.1 THA and TKA procedures improve mobility and quality of life, but patients undergoing these surgeries are at a significantly increased risk for developing postoperative venous thromboembolism (VTE).2-4 VTE
A Paradigm Shift in Anticoagulation?
It is with a great deal of pride and humility that I have accepted this new role as the Editor-in-Chief of American Health & Drug Benefits (AHDB). Let me outline what I hope to accomplish in the coming months and years and solicit your input and support. First, some background about my professional journey. I have been at Thomas Jefferson University for the past 22 years. During that tenure, I have had essentially 3 jobs. I came on board in 1990 in a staff role to the hospital CEO, directing the Office of Health Policy.
Trends in Biologic Therapies for Rheumatoid Arthritis: Results from a Survey of Payers and Providers
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disorder and the most common form of inflammatory arthritis.1 RA affects 1% of the population, most often adults aged 40 to 70 years.2 Recent epidemiologic data indicate that the incidence of RA in women has risen in the past 10 years.3 Because RA affects many individuals who are of working age and remains a major cause of disability, the economic burden of RA adds a significant cost not only to patients and their families, but also to society as a whole.1,4 In addition, reduced quality of
Biologic Therapies for Rheumatoid Arthritis: It's All about Value
Louise A. Durst, RN, John Carlsen, MHA, Megan Kuchinski, MPH, Lauren Harner, JD, Daniel Neves, BA, Stephanie J. Harris, RN, BSN, Glenna L. Traiger, RN, MSN, CNS-BC
Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by abnormally high blood pressure (ie, hypertension) in the pulmonary artery, with 1000 new cases being diagnosed annually in the United States, based on a 2009 report.1 Because of the complex nature of PAH and its treatments, healthcare providers must closely follow patients with PAH; depending on the stage of the illness, patients should generally be seen by a physician every 3 to 6 months according to the 2009 American College of Cardiology Foundation Task Force on Expert Consensus Documents and the
The Challenges of Pulmonary Arterial Hypertension Management: Potential Benefits of Removing Monthly Testing
Results 1 - 4 of 4